



Feb 28, 2020

Protocol for the systematic review of the efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension [↗](#)

PLOS One

Shaohua Huang¹, Yi Xing¹, Lijuan Zhu¹, Ke Zhang¹¹Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China[1](#) Works for me [dx.doi.org/10.17504/protocols.io.bbsfinbn](https://doi.org/10.17504/protocols.io.bbsfinbn)

ABSTRACT

Background: Fixed-combination (FC) therapy is used in primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients who require more than one medication to reach their target intraocular pressure (IOP). Currently, there are several FC therapies available for the treatment of glaucoma. The FC of latanoprost/timolol (LTFC) is a commonly used. We will conduct a systematic review to compare the IOP-lowering effects of LTFC with other FCs for patients with POAG and OHT.

Materials and methods: We will search PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized-controlled clinical trials and cross-over studies. The outcomes are mean IOP and IOP fluctuation after one month of treatment. Meta-analysis will be carried out using RevMan (version 5.1) software. After conducting meta-analyses, we will rate the quality of each meta-analysis as high, moderate, low, or very low using the "GRADE" system.

EXTERNAL LINK

<https://doi.org/10.1371/journal.pone.0229682>

THIS PROTOCOL ACCOMPANIES THE FOLLOWING PUBLICATION

Xing Y, Zhu L, Zhang K, Huang S (2020) The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. PLoS ONE 15(2): e0229682. doi: [10.1371/journal.pone.0229682](https://doi.org/10.1371/journal.pone.0229682)

ATTACHMENTS

[File Protocol.doc](#)

This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited